Lipoprotein(a): Still an enigma?

Current Opinion in Lipidology

Volumn 13, Issue 4, 2002, Pages 391-396

  Kostner, Karam M ^a   Kostner, Gerhard M ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Angiogenesis; Antisense oligonucleotides; Tissue factor pathway inhibitor

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; PLACENTA PROTEIN 5; PLASMINOGEN ACTIVATOR INHIBITOR 2;

ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CATABOLISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEMOSTASIS; HUMAN; KIDNEY; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; MONOCYTE; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; TUMOR CELL;

ANIMALS; ARTERIOSCLEROSIS; ENDOTHELIUM; HEMOSTASIS; HUMANS; KIDNEY; LIPOPROTEIN(A); RISK FACTORS;

EID: 0036326485     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200208000-00006     Document Type: Review

References (51)

1. Lipoprotein(a)
2. Apolipoprotein(a): Structure and biology
3. A new serum type system in man - The Lp system
4. Preparation of a stable fresh frozen primary lipoprotein[a] (Lp[a]) standard
5. Properties of human free apolipoprotein(a) and lipoprotein(a) after either freezing or lyophilization in the presence and absence of cryopreservatives
6. Lipoprotein(a) binding to other apolipoprotein B containing lipoproteins
7. Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins
8. Influence of remnant accumulation markers on plasma concentrations of two lipoprotein(a) subspecies (containing or free of apo-E)
9. Identification of a critical lysine residue in apolipoprotein B-100 that mediates non-covalent interaction with apolipoprotein(a)
10. Solution structure of human apolipoprotein(a) kringle IV type 6
11. Effect of low-density lipoprotein buoyant density and cholesterol content on the formation of lipoprotein(a) particles
12. The apolipoprotein(a) gene: A transcribed hyper variable locus controlling plasma lipoprotein(a) concentration
13. Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians
14. Functional analysis of the chimpanzee and human apo(a) promoter sequences: Identification of sequence variations responsible for elevated transcriptional activity in chimpanzee
15. Turnover of lipoprotein(a) in man
16. Presecretory degradation of apolipoprotein
17. Determinants of human apolipoprotein[a] secretion from mouse hepatocyte cultures
18. Reduction of LCAT, apoB and Lp(a) lipoprotein with anabolic steroid stanazolol
19. Lipoprotein(a) changes during natural menstrual cycle and ovarian stimulation with recombinant and highly purified urinary FSH
20. Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo
21. Lp(a): An interloper into the fibrinolytic system
22. Lipoprotein(a) and atherothrombotic disease
23. Kringles of the plasminogen-prothrombine gene family share conformational epitopes with recombinant apolipoprotein(a): Specificity of the fibrin-binding site
24. Inhibition of fibrinolysis by lipoprotein(a)
25. Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints
26. Characterization of the basis of lipoprotein [a] lysine-binding heterogeneity
27. Lipoprotein(a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes
28. Lipoprotein(a) binds and inactivates tissue factor pathway inhibitor: A novel link between lipoproteins and thrombosis
29. Endothelium-dependent vasorelaxation in the aorta of transgenic mice expressing human apolipoprotein(a) or lipoprotein(a)
30. Impact of apolipoprotein(a) on in vitro angiogenesis
31. Enhanced atherosclerosis in Lp(a) WHHL transgenic rabbits
32. Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits
33. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk
34. Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention trial
35. A prospective study of Lp(a) and the risk of myocardial infarction
36. Increased plasminogen activator inhibitor 1 and apolipoprotein(a) in coronary atherectomy specimens in acute coronary syndromes
37. Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms: Association with the severity of clinical presentation in patients with coronary heart disease
38. Gene expression of apolipoprotein(a) within the wall of human aorta and carotid arteries
39. Relation of Apo(a) size to carotid atherosclerosis in an elderly multi-ethnic population
40. Relationship between lipoprotein(a) levels, oxidative stress and blood pressure levels in patients with essential hypertension
41. Accumulation of atherogenic remnants and lipoprotein(a) in the nephritic syndrome: Relation to remission of proteinuria
42. Race specific association of lipoprotein(a) with vascular access interventions in hemodialysis patients: The CHOICE study
43. Impact of apolipoprotein(a) phenotypes on long term renal transplant survival
44. Urinary excretion of apo(a) fragments: Role in apo(a) catabolism
45. Urinary apo(a) discriminates coronary artery disease patients from controls
46. LDL-apheresis significantly reduces urinary apo(a) excretion
47. Urinary apo(a) excretion is not altered by changes in glomerular filtration rate in healthy males
48. Decreased urinary apo(a) excretion in patients with impaired renal function
49. Role of various tissues in apo(a) fragmentation and excretion of fragments by the kidney
50. Urinary excretion of apolipoprotein(a): Relation to other plasma proteins
51. Renal handling of human apolipoprotein(a) and its fragments in the rat